H. Michael Shepard
H. Michael Shepherd (* 1942 ) is an American molecular biologist , known for the development of genetic therapies against cancer.
Shepard graduated from the University of California, Davis with a bachelor's degree in zoology and a PhD in cell, developmental, and molecular biology from Indiana University . As a post-graduate student, he was a Fellow of the Damon Runyon Cancer Research Foundation at Indiana University.
From 1980 to 1992 he was with Genentech . Initially he was involved in the cloning of human interferon , plasminogen activators and tumor necrosis factor (TNF). He then headed a program for scientific collaboration with universities and other research institutions outside the company. A success of the program was the collaboration with Marc Feldman on the development of a TNF blocker ( Remicade ), which was used in therapies for various autoimmune diseases. He started Genentech's first translational biomedicine program. He first studied the resistance of cancer cells to TNF, and later, under his leadership, the program led to the development of trastuzumab (Herceptin), a monoclonal antibody against certain types of breast cancer.
He then decided to focus on genetic engineering drugs for cancer and left Genentech. He was one of the founders, senior scientist and vice president of research at Canji , which developed drugs and gene therapies around the p53 tumor suppressor gene . First they developed a therapy against ovarian cancer with switched off adenoviruses as the carrier of the p53 gene, but this was not further developed by the partner Schering-Plow . Then they developed a gene therapy for interferon-alpha with adenoviruses for a therapy against bladder cancer. The company he was with from 1992 to 1997 was eventually taken over by Schering-Plow.
He was also the pioneer of pan-Her drugs ( tyrosine kinase inhibitors ), which target the EGFR , HER2 and HER3 receptors .
He was the founder, president and chief scientist of Receptor BioLogix (2003-2008), which develops intron fusion protein (IFP) therapies for cancer, autoimmune and metabolic diseases.
In NewBiotics , a company he founded and in which he was from 1997 to 2002, he developed novel enzymes Catalyzed Therapeutic Agents that target enzymes that are overactive in cancer cells inactivated by p53. At Halozyme Therapeutics , where he was from 2009, he developed processes for the diffusion of drugs in cells with hyaluronidases ( Enhanze technology, PH20-mediated subcutaneous drug delivery) as their vice president and chief scientist . This enables drug treatment by subcutaneous injection, i.e. without infusion with corresponding hospital stays. The approval took place z. B. for the administration of Herceptin (Roche).
In 2006 he received the Warren Alpert Foundation Prize for the development of Herceptin. In 2019 he received the Lasker ~ DeBakey Clinical Medical Research Award .
He holds about 25 US patents.
Web links
- Biography at the San Juan Education Foundation
- Cancer Research Pioneer Dr. H. Michael Shepard Joins Anpac Bio Technical Advisory Board , biography at Biospace 2019
Individual evidence
- ^ Warren Alpert Prize for Shepard 2006
| personal data | |
|---|---|
| SURNAME | Shepard, H. Michael |
| BRIEF DESCRIPTION | American molecular biologist |
| DATE OF BIRTH | 1942 |